Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Jul 2019
Price : $35 *
At a glance
- Drugs Solanezumab (Primary)
- Indications Cognition disorders
- Focus Registrational; Therapeutic Use
- Acronyms A4
- Sponsors Eli Lilly and Company
- 11 Sep 2018 Planned End Date changed from 1 Jul 2022 to 22 Jul 2022.
- 11 Sep 2018 Planned primary completion date changed from 1 Jul 2022 to 22 Jul 2022.
- 31 Aug 2018 Biomarkers information updated